Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (Fab-IgG) (FABIG-016)

Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (Fab-IgG) is designed to be expressed as three chains, assembling in vivo and resulting in the construct of Fab-IgG (Tandem Fab-Fc). Fab-IgG has standard Fab and Fc domains, with no mutations, which may permit it has similar affinity binding and PK profile comparable to the parental antibodies. This BsAb can block cell adhesion. It is designed for the research of B cell lymphoma therapy.

Datasheet INQUIRY

Specifications

Targets

B cell lymphoma BCL1 Idiotype & CD3

Type

Fab-IgG

Species Reactivity

Mouse

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma

Targets

Target 1

B cell lymphoma BCL1 Idiotype

Alternative Names

B cell lymphoma BCL1 Idiotype; B cell lymphoma; BCL1; Idiotype; Id; 31D1; 32D1

Target 2

CD3

Gene ID

12501

UniProt ID

P24161

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3; AI504783

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Related products of "B cell lymphoma BCL1 Idiotype & CD3"

See other bsAb targets related to "CD3"

See other bsAb targets related to "B cell lymphoma BCL1 Idiotype"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (Fab-IgG) (FABIG-016). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (Fab-IgG) (CAT#: FABIG-016)

Specifications

Targets

Customer Reviews and Q&As